OKYO Pharma (NASDAQ: $OKYO), a clinical stage biopharmaceutical company, announced a major stability milestone for its drug candidate urcosimod on Monday, March 31, 2025. Details […]
Category: Red Hot Stocks
Loar Holdings (NYSE: LOAR) Releases Q4 Fiscal 2024 Results: Is This The Best Defense Stock To Buy Right Now?
Loar Holdings (NYSE: $LOAR), a diversified aerospace and defense manufacturer that supplies components to the commercial aerospace sector, business jets, and generation aviators sectors, released […]
Lululemon (NASDAQ: LULU) Sinks After Earnings Beat On Soft Guidance: Is LULU A Great Addition To Your Portfolio?
Lululemon (NASDAQ: $LULU) is a Canadian multinational athleisure retailer best known for its yoga pants, athletic wear, accessories, and lifestyle apparel. It released its Q4 […]
Alvotech (NASDAQ: ALVO) Releases Q4 Fiscal 2024 Results: Is This Biotech A Buy in 2025?
Alvotech (NASDAQ: $ALVO), a leading global biopharmaceutical manufacturer of biosimilars, released its Q4 fiscal 2024 results on Wednesday, March 26, 2024, after markets closed. Here […]
GameStop Corp. (NYSE: GME) Releases Q4 Fiscal 2024 Results: Is This Meme Stock Still A Buy?
GameStop (NYSE: $GME) is a major American retailer, primarily known for gaming consoles, video games, and gambling merchandise. It also operates stores internationally in Australia, […]
KB Home (NYSE: KBH) Misses Revenue And Earnings Estimates In Q1 Fiscal 2025: Is This Home Builder Still A Buy Amid Headwinds?
KB Home (NYSE: $KBH), a leading home building company, released its Q1 fiscal 2025 results on Monday, March 24, 2025, after markets closed. Here is […]